Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum

被引:69
作者
McGowan, John E., Jr. [1 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
关键词
D O I
10.1016/j.ajic.2006.05.226
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Nonfermenting gram-negative bacteria pose a particular difficulty for the healthcare community because they represent the problem of multidrug resistance to the maximum. Important members of the group in the United States include Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia cepacia. These organisms are niche pathogens that primarily cause opportunistic health care-associated infections in patients who are critically ill or immunocompromised. Multidrug resistance is common and increasing among gram-negative nonfermenters, and a number of strains have now been identified that exhibit resistance to essentially all commonly used antibiotics, including antipseudomonal penicillins and cephalosporins, aminoglycosides, tetracyclines, fluoroquinolones, trimethoprim-sulfamethoxazole, and carbapenems. Polymyxins are the remaining antibiotic drug class with fairly consistent activity against multidrug-resistant strains of P aeruginosa, Acinetobacter spp, and S maltophilia. However, most multidrug-resistant B cepacia are not susceptible to polymyxins, and systemic polymyxins carry the risk of nephrotoxicity for all patients treated with these agents, the elderly in particular. A variety of resistance mechanisms have been identified in P aeruginosa and other gram-negative nonfermenters, including enzyme production, overexpression of efflux pumps, porin deficiencies, and target-site alterations. Multiple resistance genes frequently coexist in the same organism. Multidrug resistance in gram-negative nonfermenters makes treatment of infections caused by these pathogens both difficult and expensive. Improved methods for susceptibility testing are needed when dealing with these organisms, including emerging strains expressing metallo-beta-lactamases. Improved antibiotic stewardship and infection-control measures will be needed to prevent or slow the emergence and spread of multidrug-resistant, nonfermenting gram-negative bacilli in the healthcare setting.
引用
收藏
页码:S29 / S37
页数:9
相关论文
共 62 条
[21]   Multidrug-resistant Acinetobacter infections:: An emerging challenge to clinicians [J].
Jain, R ;
Danziger, LH .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) :1449-1459
[22]   Burkholderia cenocepacia and Burkholderia multivorans:: influence on survival in cystic fibrosis [J].
Jones, AM ;
Dodd, ME ;
Govan, JRW ;
Barcus, V ;
Doherty, CJ ;
Morris, J ;
Webb, AK .
THORAX, 2004, 59 (11) :948-951
[23]   Emerging epidemic of metallo-β-lactamase-mediated resistances [J].
Jones, RN ;
Biedenbach, DJ ;
Sader, HS ;
Fritsche, TR ;
Toleman, MA ;
Walsh, TR .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 51 (02) :77-84
[24]  
JONES RN, 2005, 45 INT C ANT AG CHEM
[25]   Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome [J].
Kang, CI ;
Kim, SH ;
Park, WB ;
Lee, KD ;
Kim, HB ;
Kim, EC ;
Oh, MD ;
Choe, KW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :760-766
[26]   Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the united states today surveillance studies [J].
Karlowsky, JA ;
Jones, ME ;
Thornsberry, C ;
Evangelista, AI ;
Yee, YC ;
Sahm, DF .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S89-S98
[27]   Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 [J].
Karlowsky, JA ;
Draghi, DC ;
Jones, ME ;
Thornsberry, C ;
Friedland, IR ;
Sahm, DF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1681-1688
[28]   Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin [J].
Katragkou, A ;
Roilides, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (09) :4916-4917
[29]   Inadequate antimicrobial treatment of infections - A risk factor for hospital mortality among critically ill patients [J].
Kollef, MH ;
Sherman, G ;
Ward, S ;
Fraser, VJ .
CHEST, 1999, 115 (02) :462-474
[30]   Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa [J].
Kriengkauykiat, J ;
Porter, E ;
Lomovskaya, O ;
Wong-Beringer, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :565-570